Security Snapshot

Sarepta Therapeutics, Inc. - Common Stock (SRPT) Institutional Ownership

CUSIP: 803607100

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

342

Shares (Excl. Options)

93,379,419

Price

$21.52

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock
Symbol
SRPT on Nasdaq
Shares outstanding
104,849,534
Price per share
$21.76
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
93,379,419
Total reported value
$2,009,412,127
% of total 13F portfolios
0%
Share change
+7,671,068
Value change
+$171,274,911
Number of holders
342
Price from insider filings
$21.76
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • SRPT - Sarepta Therapeutics, Inc. - Common Stock is tracked under CUSIP 803607100.
  • 342 institutions reported positions in Q4 2025.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 342 to 30 between Q4 2025 and Q1 2026.
  • Reported value moved from $2,009,412,127 to $21,654,272.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 342 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 803607100?
CUSIP 803607100 identifies SRPT - Sarepta Therapeutics, Inc. - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Sarepta Therapeutics, Inc. - Common Stock (SRPT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 13% $284,766,671 13,232,652 BlackRock, Inc. 31 Dec 2025
AQR CAPITAL MANAGEMENT LLC 7.7% $171,336,931 8,104,869 AQR Capital Management, LLC 31 Dec 2025
STATE STREET CORP 5.4% $102,225,558 5,304,907 STATE STREET CORPORATION 30 Sep 2025
D. E. SHAW & CO, L.P. 1.9% -64% $38,675,372 -$58,829,132 2,007,025 -60% D. E. Shaw & Co., L.P. 30 Sep 2025
Capital International Investors 0.5% -98% $9,523,733 -$152,120,639 524,146 -94% Capital International Investors 30 Jun 2025

As of 31 Dec 2025, 342 institutional investors reported holding 93,379,419 shares of Sarepta Therapeutics, Inc. - Common Stock (SRPT). This represents 89% of the company’s total 104,849,534 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Sarepta Therapeutics, Inc. - Common Stock (SRPT) together control 68% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 14% 14,283,253 +8.2% 0.01% $307,375,600
VANGUARD GROUP INC 11% 11,810,729 +9.2% 0% $254,166,887
AQR CAPITAL MANAGEMENT LLC 7.4% 7,796,535 +455% 0.09% $167,781,432
STATE STREET CORP 6.3% 6,599,441 +24% 0% $142,019,970
Erste Asset Management GmbH 2.6% 2,728,945 +1.6% 0.49% $58,726,896
TWO SIGMA INVESTMENTS, LP 2.3% 2,441,455 +14% 0.08% $52,540,112
Aberdeen Group plc 2.1% 2,251,593 +14% 0.08% $48,454,281
TWO SIGMA ADVISERS, LP 2% 2,071,334 +5.8% 0.09% $44,575,108
UBS Group AG 2% 2,058,701 +3.4% 0.01% $44,303,245
FIRST TRUST ADVISORS LP 1.9% 1,992,577 +2.7% 0.03% $42,880,264
MORGAN STANLEY 1.8% 1,912,635 -1.8% 0% $41,159,916
GEODE CAPITAL MANAGEMENT, LLC 1.8% 1,904,325 +11% 0% $40,990,106
BANK OF AMERICA CORP /DE/ 1.6% 1,694,590 +111% 0% $36,467,583
D. E. Shaw & Co., Inc. 1.5% 1,540,390 -23% 0.03% $33,149,193
FEDERATED HERMES, INC. 1.3% 1,313,313 +0.35% 0.05% $28,262,496
RENAISSANCE TECHNOLOGIES LLC 1.1% 1,159,578 -56% 0.04% $24,954,119
CITIGROUP INC 1.1% 1,146,175 +12% 0.02% $24,665,686
Connor, Clark & Lunn Investment Management Ltd. 1% 1,082,762 -38% 0.06% $23,301,038
MILLENNIUM MANAGEMENT LLC 0.95% 1,000,109 +252% 0.02% $21,522,346
T. Rowe Price Investment Management, Inc. 0.85% 892,065 -35% 0.01% $19,198,000
Voleon Capital Management LP 0.84% 879,953 +76% 0.41% $18,936,589
VOLORIDGE INVESTMENT MANAGEMENT, LLC 0.84% 878,393 -33% 0.07% $18,903,017
683 Capital Management, LLC 0.77% 810,000 -18% 1.4% $17,431,200
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.73% 765,383 +26% 0% $16,471,042
JPMORGAN CHASE & CO 0.71% 743,988 +11% 0% $16,010,622

Institutional Holders of Sarepta Therapeutics, Inc. - Common Stock (SRPT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 1,000,663 $21,654,272 +$5,561,689 $21.76 30
2025 Q4 93,379,419 $2,009,412,127 +$171,274,911 $21.52 342
2025 Q3 86,798,814 $1,674,545,829 +$92,993,938 $19.27 313
2025 Q2 82,768,888 $1,414,059,003 -$616,173,124 $17.10 354
2025 Q1 85,664,154 $5,483,381,207 -$371,527,547 $63.82 419
2024 Q4 87,843,903 $10,682,091,570 +$115,071,840 $121.59 459
2024 Q3 86,796,388 $10,834,992,283 -$451,898,219 $124.89 451
2024 Q2 88,782,224 $14,026,709,174 +$922,747,140 $158.00 479
2024 Q1 83,236,471 $10,771,794,424 +$210,287,311 $129.46 408
2023 Q4 81,574,475 $7,866,654,991 -$295,015,527 $96.43 386
2023 Q3 83,265,476 $10,092,124,857 +$213,088,130 $121.22 390
2023 Q2 81,723,093 $9,359,752,457 +$62,411,602 $114.52 399
2023 Q1 81,211,200 $11,191,507,838 +$325,102,660 $137.83 422
2022 Q4 78,931,000 $10,227,280,074 +$92,872,677 $129.58 405
2022 Q3 78,254,620 $8,650,122,111 +$568,958,858 $110.54 364
2022 Q2 73,313,897 $5,496,320,989 +$35,960,887 $74.96 312
2022 Q1 73,015,967 $5,705,221,328 +$56,363,206 $78.12 314
2021 Q4 71,894,248 $6,474,592,585 +$536,221,296 $90.05 326
2021 Q3 65,753,485 $6,079,879,477 +$130,063,243 $92.48 297
2021 Q2 64,801,548 $5,037,256,042 -$83,636,915 $77.74 315
2021 Q1 66,263,834 $4,936,320,529 -$714,137,111 $74.53 346
2020 Q4 70,628,202 $12,036,993,873 -$160,139,710 $170.49 435
2020 Q3 72,104,327 $10,123,672,605 -$335,637,260 $140.43 393
2020 Q2 73,863,151 $11,844,121,308 +$150,679,056 $160.34 397
2020 Q1 73,412,115 $7,179,418,082 -$46,251,906 $97.82 346
2019 Q4 73,511,794 $9,484,309,752 +$56,244,489 $129.04 379
2019 Q3 73,245,840 $5,516,516,594 -$252,303,319 $75.32 329
2019 Q2 71,710,913 $10,889,813,246 +$292,081,135 $151.95 359
2019 Q1 71,059,216 $8,477,596,090 +$290,725,751 $119.19 359
2018 Q4 68,661,818 $7,492,575,765 +$726,945,004 $109.13 325
2018 Q3 61,212,693 $9,884,755,828 +$245,516,894 $161.51 336
2018 Q2 59,953,943 $7,924,528,334 +$548,877,233 $132.18 311
2018 Q1 56,761,587 $4,203,831,314 +$181,642,965 $74.09 265
2017 Q4 55,206,092 $3,072,290,058 +$54,898,638 $55.64 246
2017 Q3 53,730,465 $2,441,631,878 +$525,830,388 $45.36 229
2017 Q2 42,713,217 $1,439,533,207 +$80,813,352 $33.71 186
2017 Q1 40,738,464 $1,205,704,254 +$221,363,966 $29.60 177
2016 Q4 39,367,759 $1,079,914,087 -$175,937,880 $27.43 175
2016 Q3 42,406,897 $2,603,203,193 +$578,983,777 $61.41 183
2016 Q2 34,630,592 $660,414,393 -$14,436,681 $19.07 142
2016 Q1 35,134,647 $685,755,808 +$88,658,017 $19.52 129
2015 Q4 28,532,796 $1,100,883,608 +$34,445,813 $38.58 146
2015 Q3 27,764,899 $891,509,724 +$36,642,722 $32.11 145
2015 Q2 26,667,019 $811,458,439 +$87,268,791 $30.43 127
2015 Q1 24,203,223 $321,208,632 -$7,502,400 $13.28 111
2014 Q4 24,718,769 $357,295,111 -$43,901,247 $14.47 118
2014 Q3 25,967,938 $547,925,873 -$18,480,997 $21.10 121
2014 Q2 26,655,127 $794,069,375 +$1,202,234 $29.79 126
2014 Q1 26,596,410 $639,243,096 -$12,446,044 $24.03 114